Also, in the anti-tumor immune process, there are some other immune checkpoints, including CTLA-4, TIM3, LAG3, NKG2A, and so on, which are also recognized and participate in co-regulating immune responses with anti-PD-L1 therapy. The gene discussed is HAVCR2; the disease is neoplasm.